Literature DB >> 18201500

Nephroureterectomy for transitional cell carcinoma - the value of pre-operative histology.

Sudhanshu Chitale1, Rashidi Mbakada, Stuart Irving, Neil Burgess.   

Abstract

INTRODUCTION: Nephroureterectomy with excision of a cuff of bladder remains the standard for managing upper tract transitional cell carcinoma (TCC). Increasing use of diagnostic upper tract endoscopy has underlined the importance of obtaining a pre-operative histological diagnosis in order to avoid under-treating high-grade or multifocal disease and over-treating low-grade disease, which could, in selected cases, be managed conservatively. We review nephroureterectomy at our institution over a 10-year period with particular reference to a pre-operative histological diagnosis. PATIENTS AND METHODS: Nephroureterectomy was performed in 113 patients from February 1994 to February 2004. Of these cases, 58 were for upper tract TCC and 50 of these 58 had intravenous urography (IVU): 9 had only IVU, 28 had an additional CT scan, 5 had an additional ultrasonography and 8 had additional CT + ultrasonography for pre-operative work-up. Thirty-four of the 58 cases had retrograde pyelography. Nineteen (32.7%) of the 58 cases had a pre-operative ureteroscopy (URS) and biopsy; 14 of these had rigid URS for tumours in the lower (11) and middle (3) thirds of the ureter and 5 had flexible URS for pelvicalyceal tumours by an experienced endourologist. Thirty-one (53%) of the 58 tumours were within the pelvicalyceal system and 27 within the ureter (upper, 5; middle, 3; lower, 19). Forty-eight patients underwent a total nephroureterectomy: 40 had a two incision approach and 8 had an endoscopic resection of the lower ureter. Five of the 58 cases had a sub-total nephroureterectomy and 5 a laparoscopic nephroureterectomy with open excision of lower ureter.
RESULTS: Nineteen (32.7%) of the 58 patients had a pre-operative histological diagnosis - 17 G2pTa, 1 G1pTa, and 1 G2pT1. Fourteen (74%) biopsies matched the final postoperative histology, but 1 was down-staged, 3 up-staged and 1 up-graded compared to the original histology. Five (12.8%) of 39 patients without pre-operative histology had no TCC in the final surgical specimen: 4 (10.25%) had benign pathology such as capillary haemangioma, urothelial cysts and reactive urothelial changes while one had renal cell carcinoma (RCC).
CONCLUSIONS: This study underlines the importance of obtaining a pre-operative histological diagnosis in cases with presumed upper tract TCC. Failure to do so can result in unnecessary ablative surgery for benign disease. Such an approach can also help identify multifocality and grade of disease so that treatment of upper tract TCC can be tailored more appropriately with ablative surgery for high-grade or multifocal disease and conservative (endoscopic) therapy for low-grade disease in selected cases. Patients with suspected TCC of the upper tract should be managed at centres where facilities for the comprehensive evaluation of such tumours exist.

Entities:  

Mesh:

Year:  2008        PMID: 18201500      PMCID: PMC2216716          DOI: 10.1308/003588408X242268

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  30 in total

Review 1.  Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery?

Authors:  Jens J Rassweiler; Michael Schulze; Reinaldo Marrero; Thomas Frede; Juan Palou Redorta; Pierfrancesco Bassi
Journal:  Eur Urol       Date:  2004-12       Impact factor: 20.096

2.  Current practice patterns in urologic management of upper-tract transitional-cell carcinoma.

Authors:  Sanjay Razdan; James Johannes; Michael Cox; Demetrius H Bagley
Journal:  J Endourol       Date:  2005-04       Impact factor: 2.942

3.  Endoluminal sonographic evaluation of ureteral and renal pelvic neoplasms.

Authors:  J B Liu; D H Bagley; M J Conlin; D A Merton; A A Alexander; B B Goldberg
Journal:  J Ultrasound Med       Date:  1997-08       Impact factor: 2.153

Review 4.  Endoscopic brush cytology of the upper urinary tract. Evaluation of its efficacy and potential limitations in diagnosis.

Authors:  L G Dodd; W W Johnston; C N Robertson; L J Layfield
Journal:  Acta Cytol       Date:  1997 Mar-Apr       Impact factor: 2.319

5.  A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract.

Authors:  Grant D Stewart; Simon V Bariol; Ken M Grigor; David A Tolley; S Alan McNeill
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

6.  Computed tomography for detection and staging of transitional cell carcinoma of the upper urinary tract.

Authors:  B Planz; R George; G Adam; G Jakse; K Planz
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

7.  Ureteropyeloscopy in the diagnosis of patients with upper tract hematuria: an initial clinical study.

Authors:  T Yazaki; Y Kamiyama; H Tomomasa; H Shimizu; Y Okano; T Iiyama; T Iizumi; T Umeda
Journal:  Int J Urol       Date:  1999-05       Impact factor: 3.369

8.  Endoscopic management of upper tract urothelial tumors.

Authors:  M L Stoller; D L Gentle; M W McDonald; J H Reese; J R Tacker; P R Carroll; C Best
Journal:  Tech Urol       Date:  1997

9.  Impact of diagnostic ureteroscopy on long-term survival in patients with upper tract transitional cell carcinoma.

Authors:  B N Hendin; S B Streem; H S Levin; E A Klein; A C Novick
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

10.  Magnetic resonance imaging and computed tomography of transitional cell carcinoma of renal pelvis and ureter.

Authors:  C L Huang; G C Liu; R S Sheu; C H Huang
Journal:  Gaoxiong Yi Xue Ke Xue Za Zhi       Date:  1994-04
View more
  11 in total

1.  [Diagnostic procedures in upper urinary tract urothelial carcinoma].

Authors:  O Patschan; M Horstmann; C Thomas; H P Schlemmer; A Stenzl
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

2.  Robotic nephrectomy for central renal tumors with intraoperative evaluation of tumor histology.

Authors:  Leedor Lieberman; Ravi Barod; Alex Tapper; Ramesh Kumar; Craig Rogers
Journal:  J Robot Surg       Date:  2016-05-04

3.  Postoperative distal ureteric and bladder cuff recurrence in a Grade I renal transitional cell carcinoma diagnosed and restaged by fluorodeoxyglucose positron emission tomography-computed tomography.

Authors:  Sunita Sonavane; Deepa Rani; Ramesh Asopa; Trupti Upadhye; Dilip Pawar
Journal:  Indian J Nucl Med       Date:  2014-10

4.  Incidence of benign results after laparoscopic radical nephroureterectomy.

Authors:  Sungwoo Hong; Taekmin Kwon; Dalsan You; In Gab Jeong; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  JSLS       Date:  2014 Oct-Dec       Impact factor: 2.172

5.  The diagnostic ureteroscopy before radical nephroureterectomy in upper urinary tract urothelial carcinoma is not associated with higher intravesical recurrence.

Authors:  Hsiang-Ying Lee; Hsin-Chih Yeh; Wen-Jeng Wu; Jiun-Shiuan He; Chun-Nung Huang; Hung-Lung Ke; Wei-Ming Li; Chien-Feng Li; Ching-Chia Li
Journal:  World J Surg Oncol       Date:  2018-07-09       Impact factor: 2.754

Review 6.  Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.

Authors:  Grzegorz Fojecki; Anders Magnusson; Olivier Traxer; Joyce Baard; Palle Jörn Sloth Osther; Georg Jaremko; Christian Seitz; Thomas Knoll; Guido Giusti; Marianne Brehmer
Journal:  World J Urol       Date:  2019-03-26       Impact factor: 4.226

Review 7.  Biomarker-Oriented Therapy in Bladder and Renal Cancer.

Authors:  Mathijs P Scholtes; Arnout R Alberts; Iris G Iflé; Paul C M S Verhagen; Astrid A M van der Veldt; Tahlita C M Zuiverloon
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

8.  Investigating upper urinary tract urothelial carcinomas: a single-centre 10-year experience.

Authors:  Harveer S Dev; Stephanie Poo; James Armitage; Oliver Wiseman; Nimish Shah; Samih Al-Hayek
Journal:  World J Urol       Date:  2016-04-29       Impact factor: 4.226

9.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.

Authors:  Alison Birtle; Mark Johnson; John Chester; Robert Jones; David Dolling; Richard T Bryan; Christopher Harris; Andrew Winterbottom; Anthony Blacker; James W F Catto; Prabir Chakraborti; Jenny L Donovan; Paul Anthony Elliott; Ann French; Satinder Jagdev; Benjamin Jenkins; Francis Xavier Keeley; Roger Kockelbergh; Thomas Powles; John Wagstaff; Caroline Wilson; Rachel Todd; Rebecca Lewis; Emma Hall
Journal:  Lancet       Date:  2020-03-05       Impact factor: 79.321

10.  Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma.

Authors:  Petra Terézia Kovács; Tamás Mayer; Anita Csizmarik; Melinda Váradi; Csilla Oláh; Ádám Széles; Stephan Tschirdewahn; Ulrich Krafft; Boris Hadaschik; Péter Nyirády; Péter Riesz; Tibor Szarvas
Journal:  Biomedicines       Date:  2022-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.